PTEN and prostate carcinoma: When radiation-resistant cells and tumors derived from a p53/phosphatase and tensin homolog (PTEN)-deficient mouse model of advanced prostate cancer were treated with a lipid-based nanoformulation of Olaparib (nanoOlaparib), it made radiation-resistant tumors without BRCA mutations radiosensitive [79].